Cargando…
HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M
INTRODUCTION: HIV-1 group O (HIV-O) is a rare HIV-1 variant characterized by a high number of polymorphisms, especially in the integrase gene, e.g. positions L74I, S153A, G163Q and T206S. As HIV-O integrase enzymes have not previously been studied, our aim was to assess the impact of HIV-O integrase...
Autores principales: | Depatureaux, Agnès, Mesplède, Thibault, Quashie, Peter, Oliveira, Maureen, Moisi, Daniela, Brenner, Bluma, Wainberg, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International AIDS Society
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225329/ https://www.ncbi.nlm.nih.gov/pubmed/25397483 http://dx.doi.org/10.7448/IAS.17.4.19738 |
Ejemplares similares
-
HIV drug resistance against strand transfer integrase inhibitors
por: Anstett, Kaitlin, et al.
Publicado: (2017) -
Changes in Care Delivery for Patients with Heart Failure During the Covid-19 Pandemic: Results of a Multicenter Survey
por: McIlvennan, Colleen K., et al.
Publicado: (2020) -
Position du citoyen Tunisien vis-à-vis de la vaccination contre le virus de la COVID-19
por: Hamoudi, M.M., et al.
Publicado: (2022) -
The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound
por: Wainberg, Mark, et al.
Publicado: (2014) -
Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor
por: Quashie, Peter K., et al.
Publicado: (2015)